Targeting cancer, differently.

Our onco-metabolism approach brings
an enhanced perspective to cancer.

Learn More

Targeting cancer, differently.

Our onco-metabolism approach brings
an enhanced perspective to cancer.

Learn More

Targeting cancer, differently.

Our onco-metabolism approach brings
an enhanced perspective to cancer.

Learn More

Development Pipeline

Calithera is committed to discovering and developing first-in-class small molecule drugs to fight tumor metabolism and tumor immunology targets differently – and to make a difference for patients.

Learn More

Culture

Science

Recent News

Calithera Biosciences Presents New Preclinical Data for CB-708 at AACR Annual Meeting 2019

Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib

Calithera Biosciences Reports Fourth Quarter 2018 Financial Results and Recent Highlights

Calithera to Present at Cowen & Company 39th Annual Healthcare Conference

Calithera Biosciences to Report Fourth Quarter 2018 Financial Results on Thursday, March 7, 2019
View All